美国西弗吉尼亚大学Ali R. Rezai团队研究了超声血脑屏障开放和阿杜那单抗治疗阿尔茨海默病的效果。2024年1月3日出版的《新英格兰医学杂志》发表了这一最新研究成果。

抗淀粉样蛋白抗体已被用于降低阿尔茨海默病患者的大脑淀粉样蛋白β（Aβ）负担。研究组在每六个月输注阿杜那单抗时应用聚焦超声，以暂时打开血脑屏障，目的是在6个月的时间内增强三名参与者选定大脑区域的淀粉样蛋白去除力度。

通过氟[18F]贝他苯脑正电子发射断层扫描测量，在用聚焦超声治疗的区域中，Aβ水平的降低在数值上大于对侧半球未用聚焦超声处理的同源区域。研究组在治疗后的30至180天内进行认知测试和安全性评估。

附：英文原文

Title: Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease

Author: Ali R. Rezai, Pierre-Francois D’Haese, Victor Finomore, Jeffrey Carpenter, Manish Ranjan, Kirk Wilhelmsen, Rashi I. Mehta, Peng Wang, Umer Najib, Camila Vieira Ligo Teixeira, Tasneem Arsiwala, Abdul Tarabishy, Padmashree Tirumalai, Daniel O. Claassen, Sally Hodder, Marc W. Haut

Issue&Volume: 2024-01-03

Abstract:

Summary

Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer’s disease. We applied focused ultrasound with each of six monthly aducanumab infusions to temporarily open the blood–brain barrier with the goal of enhancing amyloid removal in selected brain regions in three participants over a period of 6 months. The reduction in the level of Aβ was numerically greater in regions treated with focused ultrasound than in the homologous regions in the contralateral hemisphere that were not treated with focused ultrasound, as measured by fluorine-18 florbetaben positron-emission tomography. Cognitive tests and safety evaluations were conducted over a period of 30 to 180 days after treatment.

DOI: 10.1056/NEJMoa2308719

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2308719